Content about IMS Health

February 7, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity.
A recent paper from the Centers for Medicare and Medicaid Services delves into these issues and more.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity. 

A recent paper from the Centers for Medicare and Medicaid Services delves into these issues and more.

Click here to read the full Generics Drug Report 2014. 

 

August 17, 2012

As the debate over healthcare reform in the United States rages — sometimes palpably so — a new report from healthcare market research firm IMS Health indicated that a major shift in drug-spending trends is under way between developed countries like the United States and developing countries.

As the debate over healthcare reform in the United States rages — sometimes palpably so — a new report from healthcare market research firm IMS Health indicated that a major shift in drug-spending trends is under way between developed countries like the United States and developing countries.

Click below to download the complete Annual Disease State Report.

April 4, 2014

IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders.

DANBURY, Conn. — IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 9.75 million shares of common stock at the public offering price, less underwriting discounts and commissions.  

March 25, 2014

Sales of specialty medicines are shifting toward hospitals and specialty pharmacies and away from independent physician owned-and-operated clinics, according to a report released Tuesday by HDMA's non-profit research foundation, The Center for Healthcare Supply Chain Research.

ARLINGTON, Va. — Sales of specialty medicines are shifting toward hospitals and specialty pharmacies and away from independent physician owned-and-operated clinics, according to a report released Tuesday by HDMA's non-profit research foundation, The Center for Healthcare Supply Chain Research. 

According to the report, independent clinics commanded 59% of distributor sales in 2012, down from 66% in 2011. Sales to hospitals and specialty pharmacies, on the other hand, increased by 6% (combined) to comprise an average of 26% of specialty distributors’ sales. 

March 25, 2014

Walgreens on Tuesday posted a sales increase of 5.1% to $19.6 billion for the second quarter ended Feb. 28. First-half sales were up 5.5% to $37.9 billion.

DEERFIELD, Ill. — Walgreens on Tuesday posted a sales increase of 5.1% to $19.6 billion for the second quarter ended Feb. 28. First half sales were up 5.5% to $37.9 billion. 

March 24, 2014

IMS Health Holdings is expected to launch an initial public stock offering in two weeks, according to a report Sunday in the Wall Street Journal.

NEW YORK — IMS Health Holdings is expected to launch an initial public stock offering in two weeks, according to a report Sunday in the Wall Street Journal. The syndicated prescription data service could be valued as much as $7 billion, WSJ noted, citing people familiar with the matter, with a per-share price of as much as $21. 

March 12, 2014

Three-in-four pharmaceutical companies are looking to derive greater value from the influx of healthcare information that includes anonymized electronic medical records and other real-world data, according to a report issued by the IMS Institute for Healthcare Informatics on Wednesday. New investments in a range of commercial operations applications — such as customer relationship management, social media or integrated multi-channel marketing solutions — were cited by more than 70% of respondents as a priority.

PARSIPPANY, N.J. — Three-in-four pharmaceutical companies are looking to derive greater value from the influx of healthcare information that includes anonymized electronic medical records and other real-world data, according to a report issued by the IMS Institute for Healthcare Informatics on Wednesday. New investments in a range of commercial operations applications — such as customer relationship management, social media or integrated multi-channel marketing solutions — were cited by more than 70% of respondents as a priority.

February 18, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity.

February 18, 2014

To put it in Facebook terms, the pharmaceutical industry by and large has yet to friend American consumers.

To put it in Facebook terms, the pharmaceutical industry by and large has yet to friend American consumers.

A new report from the IMS Institute for Healthcare Informatics concludes that fewer than half of the top 50 global pharmaceutical manufacturers “have some level of healthcare social media engagement.” This, despite the fact that “increasingly, patients are turning to social media as an essential forum for obtaining and sharing information related to their health,” noted Murray Aitken, the institute’s executive director.

January 21, 2014

With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.

PARSIPPANY, N.J. — With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics. 

January 17, 2014

Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets. 

According to IMS Health data, annual U.S. sales of digoxin tablets are approximately $44 million. 

January 7, 2014

Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

BAUDETTE, Minn. — Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

January 3, 2014

IMS Health is looking to go public, the healthcare industry research and analytics company said.

DANBURY, Conn. — IMS Health is looking to go public, the healthcare industry research and analytics company said.

IMS, based in Danbury, Conn., said it had filed with the Securities and Exchange Commission for a proposed initial public offering of its common stock, adding that it had not yet determined the number of shares to be offered or the price range of the offering.

December 26, 2013

Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years.

Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years. But according to IMS’ latest figures, it was not the start of a trend.

December 18, 2013

The U.S. healthcare system saved $217 billion in 2012 thanks to the use of generic drugs, according to a new report by a generic drug industry trade group.

WASHINGTON — The U.S. healthcare system saved $217 billion in 2012 thanks to the use of generic drugs, according to a new report by a generic drug industry trade group.

November 19, 2013

Global spending on drugs will pass the $1 trillion mark next year, according to a new study by the IMS Institute for Healthcare Informatics, a division of healthcare market analysis firm IMS Health.

NEW YORK — Global spending on drugs will pass the $1 trillion mark next year, according to a new study by the IMS Institute for Healthcare Informatics, a division of healthcare market analysis firm IMS Health.

November 8, 2013

The United States is leading in its preference for generic drugs. According to a new report by Rhinebeck, N.Y.-based Phoenix Marketing International, 37% of American consumers expressed a preference for generic drugs when they were available, compared with 22% of the French, 21% of Canadians and 12% of Britons. The study was based on 810 consumers in the four countries.

The United States is leading in its preference for generic drugs. According to a new report by Rhinebeck, N.Y.-based Phoenix Marketing International, 37% of American consumers expressed a preference for generic drugs when they were available, compared with 22% of the French, 21% of Canadians and 12% of Britons. The study was based on 810 consumers in the four countries.

November 1, 2013

A new study by IMS Health finds that most apps focused on health and wellness have limited functionality or evidence of value in advancing healthcare provision and outcomes, with fewer than half of them directly related to patient health and treatment, and more than half of them having fewer than 500 downloads.

With more than 43,000 health-and-wellness apps from the Apple App Store alone included in the IMS study, but a dearth of apps for elderly patients with chronic conditions, there is ample opportunity for developers to address this need. That will become especially important as health care becomes increasingly focused on patient outcomes. And this means opportunities for apps that address the ever-present issue of poor medication adherence.

A new study by IMS Health finds that most apps focused on health and wellness have limited functionality or evidence of value in advancing healthcare provision and outcomes, with fewer than half of them directly related to patient health and treatment, and more than half of them having fewer than 500 downloads.

October 31, 2013

The "vast majority" of available mobile apps focused on health and wellness have limited functionality or evidence of value in advancing healthcare provision and outcomes, according to a new report by IMS Health.

PARSIPPANY, N.J. — The "vast majority" of available mobile apps focused on health and wellness have limited functionality or evidence of value in advancing healthcare provision and outcomes, according to a new report by IMS Health.

October 10, 2013

While the boom in generic drugs now looks set to wane, another segment of the pharmaceutical industry is rapidly rising and presenting new growth opportunities for pharmacy retailers: specialty drugs.

While the boom in generic drugs now looks set to wane, another segment of the pharmaceutical industry is rapidly rising and presenting new growth opportunities for pharmacy retailers: specialty drugs.

September 10, 2013

Ranbaxy Labs recently marked the 20th anniversary of its operations in Russia, the India-based generic drug company announced.

GURGAON, India — Ranbaxy Labs recently marked the 20th anniversary of its operations in Russia, the India-based generic drug company announced.

Ranbaxy established its operations in the Russian market in 1993 with the launch of its key brand, Cifran, and since then, it has grown to command a market share of 15.4% in the country, according to IMS Health.

September 10, 2013

This year's spring allergy season has been characterized by a late start. "The allergy season was very weak in February and March, and even the beginning of April [was] very weak," William Peters, CFO and VP finance for Hi-Tech Pharmacal, told analysts in July.

This year's spring allergy season has been characterized by a late start. "The allergy season was very weak in February and March, and even the beginning of April [was] very weak," William Peters, CFO and VP finance for Hi-Tech Pharmacal, told analysts in July. "June was more consistent with the previous year," he added.

September 10, 2013

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

August 20, 2013

It’s been a week since the National Association of Chain Drug Stores wrapped up its massive Total Store Expo pow-wow in Las Vegas. Hundreds of retail pharmacy industry vendors have broken down their exhibits and cleared the cavernous Sands Expo Center for the next big event. By last Wednesday, the exodus of more than 5,700 exhausted conference-goers from Sin City had slowed to a trickle.

It’s been a week since the National Association of Chain Drug Stores wrapped up its massive Total Store Expo pow-wow in Las Vegas. Hundreds of retail pharmacy industry vendors have broken down their exhibits and cleared the cavernous Sands Expo Center for the next big event. By last Wednesday, the exodus of more than 5,700 exhausted conference-goers from Sin City had slowed to a trickle.

August 14, 2013

IMS Health VP of supplier services Jim Hunter and IMS VP of industry relations Doug Long presented Rite Aid EVP of pharmacy Robert Thompson with IMS' Bernie Greenberg Pharmacy Partnership Award at the NACDS Total Store Expo.

LAS VEGAS — IMS Health VP of supplier services Jim Hunter and IMS VP of industry relations Doug Long on Monday presented Rite Aid EVP of pharmacy Robert Thompson with IMS' Bernie Greenberg Pharmacy Partnership Award at the NACDS Total Store Expo here.